Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

21.36 +0.41 (+1.96%)
Streaming Delayed Price Updated: 11:05 AM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
A Closer Look at 5 Analyst Recommendations For Beam Therapeutics
 
Via Benzinga
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1... 
Via Benzinga
3 Gene Editing Stocks with Potential to Transform Medicine
Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. 
Via InvestorPlace
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Expert Ratings For Beam Therapeutics
 
Via Benzinga
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Beam Therapeutics Stock Earns RS Rating Jump To 85
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
Why Is Conn’s (CONN) Stock Down 36% Today?
Conn’s stock is falling on Wednesday as CONN investors react to reports of potential store closures and a bankruptcy filing. 
Via InvestorPlace
Topics Bankruptcy
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
Beam Therapeutics recently got a vote of confidence from a Wall Street analyst, providing fuel for further upside in BEAM stock. 
Via InvestorPlace
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
3 Gene Editing Stocks Shaping the Future of Medicine
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions 
Via InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
 
Via Benzinga
Beam Therapeutics Announces Transition of Chief Financial Officer
From Beam Therapeutics
Via GlobeNewswire
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
Via InvestorPlace
3 Stocks With the Potential to 10X Your Money
These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost. 
Via InvestorPlace
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
These high-risk, high-reward stocks have the potential to turn $1K into $1M by 2030, according to Amazon-backed AI Claude 3.5 Sonnet. 
Via InvestorPlace
Topics Artificial Intelligence
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects. 
Via InvestorPlace
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
From Beam Therapeutics
Via GlobeNewswire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.